信达生物(01801)与礼来制药的战略合作已生效 澄清非收购交易

Core Viewpoint - The strategic cooperation agreement between the company and Eli Lilly for drug development in oncology and immunology has been officially approved and is now effective as of March 24, 2026 [1] Group 1 - The company announced the signing of a strategic cooperation agreement with Eli Lilly on February 8, 2026, aimed at advancing new drug research in oncology and immunology [1] - The Federal Trade Commission has granted early approval for the agreement, fulfilling all necessary conditions for its effectiveness [1] - The company clarified that some media reports incorrectly interpreted the agreement's effectiveness as an acquisition of the company, emphasizing that there is no intention to pursue such transactions [1]